NextCure reports positive Phase 1 data for cancer drug SIM0505

NextCure, Inc. has presented encouraging Phase 1 dose escalation data for its investigational drug candidate, SIM0505, at the ASCO 2026 conference. The study demonstrated a 55% overall response rate in patients with gynecologic cancers, along with a favorable safety and tolerability profile. These positive results support the continuation of dose-optimization studies for the treatment.